People with diabetes are more likely to develop a cardiovascular (CV) disease compared
with those without diabetes. Although effective glycemic control has been the focus of the …

OBJECTIVE To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose
cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D) …

Background Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor that
reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin,
and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus …

Introduction Coronary heart disease, stroke, and peripheral vascular disease are the most
common causes of mortality in patients with type 2 diabetes mellitus (T2DM). The aim of …

Importance Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal
glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart …

Aims To evaluate comprehensively the safety of dapagliflozin in patients with type 2
diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium …

Background A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase
2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of …

Dapagliflozin is a selective and reversible inhibitor of sodium–glucose linked transporter
type 2 (SGLT2), which mediates approximately 90% of active renal glucose reabsorption in …